papillomaviruses selectively multiply in epithelial cells, the capsids may be particularly useful for mucosal vaccines, and for delivering genes to epithelial tissues. The existence of many non-crossreacting serotypes of human papillomaviruses can be taken advantage of to eliminate the problem of immune rejection of a pseudoviral particle. The same gene or antigen encoding DNA can be incorporated in pseudoviral particles of different serotypes for multiple dosing. The inventors have demonstrated delivery of the neomycin resistance gene to mammalian cells with a BPV capsid encapsidating a vector consisting of the neomycin gene under control of a mammalian promoter and DNA containing E2 binding sites. Claimed are the pseudoviral particles, methods of making them, and methods of using them.

Method of Inhibiting The Activity of an Intracellular Constituent

MJ Mulligan-Kehoe (NCI)
U.S. Patent 5,702,892 issued 30 Dec 97; Serial No. 08/897,040 filed 18 Jul 97; Serial No. 09/096,889 filed 12 Jun 98
Licensing Contract: Marlene Shinn, 301/496–7056 ext. 285

Two combinatorial libraries of binding proteins have been engineered. The libraries were designed to genetically shuffle oligonucleotide motifs within the framework of the immunoglobulin heavy chain gene by random mutation of either the CDRI or CDRIII hypervariable regions. The Fd fragment of the heavy chain gene was then reconstructed such that it contained the randomized oligonucleotides in the hypervariable region, resulting in a collection of highly diverse sequences. The libraries of heavy chain proteins encoded by the array of mutated gene sequences potentially have all of the binding characteristics of an immunoglobulin while requiring only the heavy chain Fd protein.

The re-engineered heavy chain gene sequences were ligated into a M13-derived bacteriophage vector that permits expression of the binding proteins as fusion proteins with viral protein 8, which is expressed on the phage surface.

The claims of the patent application provide methods to screen the libraries, to identify the binding protein to a specific antigen and the gene for that specific protein, and to re-engineer the gene for intracellular expression in a eukaryotic cell. Inducible intracellular inactivation of glucose-6-phosphate dehydrogenase (G6PDH) has been demonstrated by in vivo expression of a gene construct encoding a binding protein selected from one of the libraries and specific for G6PDH. Removal of induction restored the enzyme activity.

The libraries of binding proteins, the screening methods, and the methods of inhibiting intracellular components claimed in the patent application provide powerful potential tools for cellular and molecular biology by affording the capability of binding/inactivating any protein of choice.

Amino Acid Sequencing Peptides and Methods for Their Use

DC Parmelee, S Sechi (NCI)
U.S. Patent 5,589,397 issued 31 Dec 96; Serial No. 08/739,819 filed 30 Oct 96
Licensing Contract: Manja Blazer, 301/496–7056 ext. 224

The present invention provides a novel internal standard for amino acid sequencing which consist of a peptide containing at least two different unnatural amino acid residues, such as ornithine, norvaline, norleucine and α-aminobutyric acid. The PTH-derivatives of these have retention times distinct from those of natural amino acids. This peptide can be sequenced simultaneously with an unknown peptide or protein without interfering with the analysis. Simultaneous sequencing of this standard provides information which allows for the determination of repetitive yields, lags, N-terminal blockage and discrimination between blank cycles caused by missed injection and blank cycles caused by faulty delivery of chemicals during the sequencing reactions.

Dated: November 30, 1998.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 98–32318 Filed 12–3–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel.

Date: December 3, 1998.

Time: 2:00 PM to 3:00 PM.

Agenda: To review and evaluate contract proposals.

Place: NIH/NINDS, Federal Building, Room 9C10, 7550 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Phillip F. Wiethorn, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, NINDS, National Institutes of Health, PHS, DHHS, Federal Building, Room 9C10, 7550 Wisconsin Avenue, Bethesda, MD 20892, 301–496–9223.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: November 30, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–32312 Filed 12–3–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, NIAAA.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance